Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLX1570 and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02372240Phase 2Terminated
- Sponsor
- Vivolux
- Start
- Apr 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vlx1570 in multiple myeloma (MM), sponsored by Vivolux. Primary endpoints: Maximum Tolerated Dose and Clinical Benefit Rate up to 2 years. Started Apr 2015; status: terminated.
02
Drugs
vlx1570
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02372240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372240.